|
Using real-world data to investigate time-dependent blood count response to PD-1 and PD-L1 inhibitors and its impact on survival in advanced non-small cell lung cancers. |
|
|
|
|
|
|
|
|
|
Stock and Other Ownership Interests - Sema4 |
|
|
|
|
|
|
|
|
Employment - Sema4; Sema4 (I) |
|
|
|
|
|
|
Stock and Other Ownership Interests - Lilly; Merck; Sema4 |
Travel, Accommodations, Expenses - Sema4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
No Relationships to Disclose |
|
|
Employment - Sema4; Sema4 (I) |
|
|
|
|
|
|
Stock and Other Ownership Interests - Personalis; Sema4 |
Patents, Royalties, Other Intellectual Property - I hold patent and royalty with Personalis, Boston University, Stanford University, and Quest Diagnostics. |